Skip to Content

Nader Fotouhi, PhD ’88

Drug discovery career culminates in quest for new TB treatments
February 26, 2020
TB Alliance

When a headhunter phoned Nader Fotouhi, PhD ’88, six years ago about an opportunity with a nonprofit tuberculosis drug developer called TB Alliance, he said he was the wrong person for the job.

Fotouhi had recently retired from the multinational health care company Hoffman–La Roche after a long career in drug discovery and development, but he had never worked with anti-infectives. His curiosity was piqued by the new opportunity, however, and he began researching the disease.

What he found alarmed him.

“I literally couldn’t stop reading and learning about TB, the devastation, and the number of people who were dying each year,” recalls Fotouhi. “It’s just a horrible disease, and it’s mostly affecting poor people.” A global airborne disease and the leading infectious cause of death worldwide, according to the World Health Organization, tuberculosis kills an estimated 1.5 million people a year, with about 500,000 suffering from drug-resistant forms.

Fotouhi accepted the job. And as TB Alliance’s chief scientific officer, he has helped the nonprofit, which is headquartered in New York City and South Africa, establish a strong foundation of new drug candidates that, when used in the right combination, can be the basis of shorter, more effective treatments.

The antibiotics developed by TB Alliance include pretomanid, which was approved as part of a three-drug TB regimen in August by the Food and Drug Administration. It is only the third new anti-TB drug approved for use by the FDA in more than 40 years, as well as the first to be developed and registered by a nonprofit. The Alliance also has about 30 other projects in discovery and development.

“It’s all about decision-making and doing the right projects—knowing when to stop and betting your money on things that could be productive and make it to the finish line,” says Fotouhi. He credits the MIT chemistry department with teaching him how to think analytically, challenge himself, and ask the right questions before seeking answers.

“I realized there,” he says, “that I can learn anything.”

Current regimens for drug-resistant TB often require taking as many as 20 pills daily for up to two years, a routine many find difficult to complete. In contrast, pretomanid is approved for use with just two other medications over six months. Ongoing research could further speed and simplify treatment, Fotouhi says.

“If we can one day shorten it to three months and only three pills a day, that significantly reduces the burden,” he says.

Keep Reading

Most Popular

Workers disinfect the street outside Shijiazhuang Railway Station
Workers disinfect the street outside Shijiazhuang Railway Station

Why China is still obsessed with disinfecting everything

Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Europe's AI Act concept
Europe's AI Act concept

A quick guide to the most important AI law you’ve never heard of

The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.